ClinicalTrials.gg
CompletedNCT02120300Updated Dec 6, 2016Results posted

Efficacy and Safety of Ledipasvir/Sofosbuvir Fixed-Dose Combination and Sofosbuvir + Ribavirin for Subjects With Chronic Hepatitis C Virus (HCV) and Inherited Bleeding Disorders

A Phase 2 interventional study of LDV/SOF and SOF in Chronic HCV Infection, sponsored by Gilead Sciences. Completed at 13 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-12-06.

Sponsored by Gilead Sciences · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
122
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The primary objectives of this study are to evaluate the antiviral efficacy, safety, and tolerability of treatment with ledipasvir/sofosbuvir (LDV/SOF) fixed-dose combination (FDC) in participants with genotypes 1 and 4 hepatitis C virus (HCV) infection and sofosbuvir (SOF) plus ribavirin (RBV) in participants with genotypes 2 and 3 HCV infection. Participants with an inherited bleeding disorder and chronic HCV infection (either monoinfected or HIV-1/HCV coinfected) will be enrolled.

02

Conditions studied

  • Chronic HCV Infection
03

In context

Lead sponsor

Gilead Sciences is the lead sponsor of 692 studies on the registry; 26 are open to participants now.

Of its 261 completed or terminated interventional studies of FDA-regulated products, 251 (96%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Hemophilia A, B or C, or Von Willebrand's disease
  • Chronic genotype 1, 2, 3 or 4 infection
  • HCV RNA ≥ 1000 IU/mL at screening
  • Use of protocol specified method(s) of if female of or sexually active male
  • Screening laboratory values within defined thresholds
  • For -1/HCV co-infected individuals:

    • Suppressed HIV-1 RNA on an antiretroviral (ARV) regimen for at least 6 months prior to screening
    • Stable protocol-approved ARV regimen for > 8 weeks prior to screening
    • > 200 cells/mm\^3 at screening

Exclusion criteria

Exclusion Criteria:

  • Clinically-significant illness (other than , inherited bleeding disorder or -1) or any other major medical disorder that may interfere with subject treatment, assessment or compliance with the protocol
  • Current or prior history of any of the following:

    • Hepatic decompensation
    • Chronic liver disease of a non-HCV etiology
    • Hepatocellular carcinoma (HCC)
    • Infection with virus (HBV)
  • Pregnant or nursing female
  • Prior treatment with inhibitors of nonstructural protein 5A (NS5A) or the NS5B polymerase
  • Chronic use of systemically administered agents
  • For HIV-1/HCV co-infected individuals:

    • Opportunistic infection within 6 months prior to screening
    • Active, serious infection (other than HIV-1 or HCV) requiring parental antibiotics, antivirals or antifungals within 30 days prior to baseline
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
122 participants (actual)

Study arms

  • Experimental
    LDV/SOF GT 1 or 4

    Participants with chronic genotypes (GT) 1 or 4 HCV infection will receive LDV/SOF for 12 or 24 weeks. Treatment-experienced cirrhotic participants with genotype 1 HCV infection will receive LDV/SOF for 24 weeks.

    Drug: LDV/SOF

  • Experimental
    SOF+RBV 12 wks GT 2

    Participants with chronic genotype 2 HCV infection will receive SOF+RBV for 12 weeks.

    Drug: SOF · Drug: RBV

  • Experimental
    SOF+RBV 24 wks GT 3

    Participants with chronic genotype 3 HCV infection will receive SOF+RBV for 24 weeks.

    Drug: SOF · Drug: RBV

Interventions

  • DrugLDV/SOF

    90/400 mg FDC tablet administered orally

    Also known as: Harvoni®, GS-5885/GS-7977

  • DrugSOF

    400 mg tablet administered orally once daily

    Also known as: Sovaldi®, GS-7977, PSI-7977

  • DrugRBV

    Ribavirin (RBV) tablets administered orally in a divided daily dose according to package insert weight-based dosing recommendations (\< 75 kg = 1000 mg and ≥ 75 kg = 1200 mg)

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)

    SVR12 was defined as HCV RNA \< the lower limit of quantitation (LLOQ; ie, 15 IU/mL) at 12 weeks after stopping study treatment.

    Time frame: Posttreatment Week 12

  2. Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event

    Time frame: Up to 24 weeks

Secondary outcomes

  1. Percentage of Participants With SVR at 4 Weeks After Discontinuation of Therapy (SVR4)

    SVR4 was defined as HCV RNA \< LLOQ at 4 weeks after stopping study treatment.

    Time frame: Posttreatment Week 4

  2. Percentage of Participants With HCV RNA < LLOQ at Weeks 1, 2, 4, 8, 12, 16, 20, and 24

    Time frame: Weeks 1, 2, 4, 8, 12, 16, 20, and 24

  3. Change From Baseline in HCV RNA at Weeks 1, 2, 4, 8, 12, 16, 20, and 24

    Time frame: Baseline; Weeks 1, 2, 4, 8, 12, 16, 20, and 24

  4. Percentage of Participants With Virologic Failure

    Virologic failure was defined as: * On-treatment virologic failure: * Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA \< LLOQ while on treatment), or * Rebound (confirmed \> 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or * Non-response (HCV RNA persistently ≥ LLOQ through 8 weeks of treatment) * Virologic relapse: * Confirmed HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA \< LLOQ at last on-treatment visit.

    Time frame: Up to Posttreatment Week 24

  5. Percentage of Participants That Maintain HIV-1 RNA < 50 Copies/mL at Weeks 4, 8, 12, 16, 20, and 24 (HIV-1/HCV Co-infected Participants Only)

    Time frame: Weeks 4, 8, 12, 16, 20, and 24

  6. Change From Baseline in Serum Creatinine at the End of Treatment and at Posttreatment Week 12 (HIV-1/HCV Co-infected Participants Only)

    Time frame: Baseline; Weeks 12, 24, and Posttreatment Week 12

07

Results

Posted Dec 6, 2016
Limitations and caveats
There were no limitations affecting the analysis or results.

Participant flow

Participants were enrolled at study sites in the United States. The first participant was screened on 10 April 2014. The last study visit occurred on 17 August 2015.

Participant flow — Overall Study
MilestoneLDV/SOF 12 Weeks GT1 or GT4LDV/SOF 24 Weeks GT1 (TE)SOF+RBV 12 Weeks GT2SOF+RBV 24 Weeks GT3
Started1015106
Completed985105
Not completed3001
Withdrew: Enrolled but never treated2000
Withdrew: Lack of efficacy0001
Withdrew: Lost to follow-up1000

Outcome measures

PrimaryPercentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)

SVR12 was defined as HCV RNA \< the lower limit of quantitation (LLOQ; ie, 15 IU/mL) at 12 weeks after stopping study treatment.

Time frame:
Posttreatment Week 12
Reported as:
Number · percentage of participants
Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)
percentage of participantsLDV/SOF 12 Weeks GT1 or GT4LDV/SOF 24 Weeks GT1 (TE)SOF+RBV 12 Weeks GT2SOF+RBV 24 Weeks GT3
Percentage of Participants With Sustained Virologic Response (SVR) 12 Weeks After Discontinuation of Therapy (SVR12)99.0 (94.5 to 100.0)100.0 (47.8 to 100.0)100.0 (69.2 to 100.0)83.3 (35.9 to 99.6)
PrimaryPercentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event
Time frame:
Up to 24 weeks
Reported as:
Number · percentage of participants
Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event
percentage of participantsLDV/SOF 12 Weeks GT1 or GT4LDV/SOF 24 Weeks GT1 (TE)SOF+RBV 12 Weeks GT2SOF+RBV 24 Weeks GT3
Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event0000
SecondaryPercentage of Participants With SVR at 4 Weeks After Discontinuation of Therapy (SVR4)

SVR4 was defined as HCV RNA \< LLOQ at 4 weeks after stopping study treatment.

Time frame:
Posttreatment Week 4
Reported as:
Number · percentage of participants
Percentage of Participants With SVR at 4 Weeks After Discontinuation of Therapy (SVR4)
percentage of participantsLDV/SOF 12 Weeks GT1 or GT4LDV/SOF 24 Weeks GT1 (TE)SOF+RBV 12 Weeks GT2SOF+RBV 24 Weeks GT3
Percentage of Participants With SVR at 4 Weeks After Discontinuation of Therapy (SVR4)99.0 (94.5 to 100.0)100.0 (47.8 to 100.0)100.0 (69.2 to 100.0)83.3 (35.9 to 99.6)
SecondaryPercentage of Participants With HCV RNA < LLOQ at Weeks 1, 2, 4, 8, 12, 16, 20, and 24
Time frame:
Weeks 1, 2, 4, 8, 12, 16, 20, and 24
Reported as:
Number · percentage of participants
Percentage of Participants With HCV RNA < LLOQ at Weeks 1, 2, 4, 8, 12, 16, 20, and 24
percentage of participantsLDV/SOF 12 Weeks GT1 or GT4LDV/SOF 24 Weeks GT1 (TE)SOF+RBV 12 Weeks GT2SOF+RBV 24 Weeks GT3
Week 128.320.020.016.7
Week 268.740.070.033.3
Week 494.9100.0100.066.7
Week 8100.0100.0100.0100.0
Week 1299.0100.0100.0100.0
Week 16NA100.0NA100.0
Week 20NA100.0NA100.0
Week 24NA100.0NA100.0
SecondaryChange From Baseline in HCV RNA at Weeks 1, 2, 4, 8, 12, 16, 20, and 24
Time frame:
Baseline; Weeks 1, 2, 4, 8, 12, 16, 20, and 24
Reported as:
Mean · log10 IU/mL
Change From Baseline in HCV RNA at Weeks 1, 2, 4, 8, 12, 16, 20, and 24
log10 IU/mLLDV/SOF 12 Weeks GT1 or GT4LDV/SOF 24 Weeks GT1 (TE)SOF+RBV 12 Weeks GT2SOF+RBV 24 Weeks GT3
Baseline6.21 ± 0.6736.02 ± 0.8476.20 ± 1.0026.6 ± 0.803
Week 1 (LDV/SOF 12 Weeks: n= 98)-4.41 ± 0.580-4.32 ± 0.815-4.39 ± 0.633-3.95 ± 0.473
Week 2 (LDV/SOF 24 Week: n=4)-4.87 ± 0.642-4.65 ± 0.967-5.01 ± 0.965-4.76 ± 0.797
Week 4-5.05 ± 0.662-4.87 ± 0.847-5.05 ± 1.002-5.26 ± 0.786
Week 8-5.06 ± 0.673-4.87 ± 0.847-5.05 ± 1.002-5.45 ± 0.803
Week 12 (LDV/SOF 12 Weeks: n= 98)-5.06 ± 0.675-4.87 ± 0.847-5.05 ± 1.002-5.45 ± 0.803
Week 16NA ± NA-4.87 ± 0.847NA ± NA-5.45 ± 0.803
Week 20NA ± NA-4.87 ± 0.847NA ± NA-5.45 ± 0.803
Week 24NA ± NA-4.87 ± 0.847NA ± NA-5.45 ± 0.803
SecondaryPercentage of Participants With Virologic Failure

Virologic failure was defined as: * On-treatment virologic failure: * Breakthrough (confirmed HCV RNA ≥ LLOQ after having previously had HCV RNA \< LLOQ while on treatment), or * Rebound (confirmed \> 1 log10 IU/mL increase in HCV RNA from nadir while on treatment), or * Non-response (HCV RNA persistently ≥ LLOQ through 8 weeks of treatment) * Virologic relapse: * Confirmed HCV RNA ≥ LLOQ during the posttreatment period having achieved HCV RNA \< LLOQ at last on-treatment visit.

Time frame:
Up to Posttreatment Week 24
Reported as:
Number · percentage of participants
Percentage of Participants With Virologic Failure
percentage of participantsLDV/SOF 12 Weeks GT1 or GT4LDV/SOF 24 Weeks GT1 (TE)SOF+RBV 12 Weeks GT2SOF+RBV 24 Weeks GT3
Percentage of Participants With Virologic Failure00016.7
SecondaryPercentage of Participants That Maintain HIV-1 RNA < 50 Copies/mL at Weeks 4, 8, 12, 16, 20, and 24 (HIV-1/HCV Co-infected Participants Only)
Time frame:
Weeks 4, 8, 12, 16, 20, and 24
Reported as:
Number · percentage of participants
Percentage of Participants That Maintain HIV-1 RNA < 50 Copies/mL at Weeks 4, 8, 12, 16, 20, and 24 (HIV-1/HCV Co-infected Participants Only)
percentage of participantsLDV/SOF 12 Weeks GT1 or GT4SOF+RBV 12 Weeks GT2SOF+RBV 24 Weeks GT3
Week 4100100100
Week 8100100100
Week 12100100100
Week 16NANA100
Week 20NANA100
Week 24NANA66.7
SecondaryChange From Baseline in Serum Creatinine at the End of Treatment and at Posttreatment Week 12 (HIV-1/HCV Co-infected Participants Only)
Time frame:
Baseline; Weeks 12, 24, and Posttreatment Week 12
Reported as:
Mean · mg/dL
Change From Baseline in Serum Creatinine at the End of Treatment and at Posttreatment Week 12 (HIV-1/HCV Co-infected Participants Only)
mg/dLLDV/SOF 12 Weeks GT1 or GT4SOF+RBV 12 Weeks GT2SOF+RBV 24 Weeks GT3
Baseline0.94 ± 0.1971.01 ± 0.1180.94 ± 0.086
Week 120.04 ± 0.079-0.03 ± 0.095-0.03 ± 0.093
Week 24NA ± NANA ± NA-0.08 ± 0.069
Posttreatment Week12-0.01 ± 0.113-0.08 ± 0.015-0.02 ± 0.081

Adverse events

Collected over Up to 24 weeks plus 30 days. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
LDV/SOF 12 Weeks GT1 or GT4—5/99 (5.1%)54/99 (54.5%)
LDV/SOF 24 Weeks GT1 (TE)—0/5 (0%)3/5 (60%)
SOF+RBV 12 Weeks GT2—0/10 (0%)8/10 (80%)
SOF+RBV 24 Weeks GT3—1/6 (16.7%)4/6 (66.7%)
Most frequent serious events
Most frequent serious events
EventLDV/SOF 12 Weeks GT1 or GT4LDV/SOF 24 Weeks GT1 (TE)SOF+RBV 12 Weeks GT2SOF+RBV 24 Weeks GT3
Cholecystitis acuteHepatobiliary disorders0/990/50/101/6
HaemarthrosisMusculoskeletal and connective tissue disorders2/990/50/100/6
Gastrointestinal haemorrhageGastrointestinal disorders1/990/50/100/6
Lower gastrointestinal haemorrhageGastrointestinal disorders1/990/50/100/6
Suicidal ideationPsychiatric disorders1/990/50/100/6
Miscarriage of partnerSocial circumstances1/990/50/100/6
HaematomaVascular disorders1/990/50/100/6
Most frequent other events
Showing 10 of 37
Most frequent other events
EventLDV/SOF 12 Weeks GT1 or GT4LDV/SOF 24 Weeks GT1 (TE)SOF+RBV 12 Weeks GT2SOF+RBV 24 Weeks GT3
DiarrhoeaGastrointestinal disorders7/990/51/103/6
InsomniaPsychiatric disorders6/990/51/103/6
ConstipationGastrointestinal disorders1/992/50/100/6
FatigueGeneral disorders29/991/53/102/6
Sinus congestionRespiratory, thoracic and mediastinal disorders0/990/51/102/6
HeadacheNervous system disorders14/990/53/100/6
Food poisoningGastrointestinal disorders0/991/50/100/6
Influenza like illnessGeneral disorders1/991/50/100/6
Muscle strainInjury, poisoning and procedural complications1/991/50/100/6
HaemorrhageVascular disorders0/991/50/100/6

Baseline characteristics

Safety Analysis Set: participants who received at least 1 dose of study drug.

Age, Continuous
Age, Continuous(Years)LDV/SOF 12 Weeks GT1 or GT4LDV/SOF 24 Weeks GT1 (TE)SOF+RBV 12 Weeks GT2SOF+RBV 24 Weeks GT3Total
Mean44 ± 11.149 ± 11.148 ± 13.847 ± 6.745 ± 11.1
Sex: Female, Male
Sex: Female, Male(Participants)LDV/SOF 12 Weeks GT1 or GT4LDV/SOF 24 Weeks GT1 (TE)SOF+RBV 12 Weeks GT2SOF+RBV 24 Weeks GT3Total
Female60107
Male93596113
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)LDV/SOF 12 Weeks GT1 or GT4LDV/SOF 24 Weeks GT1 (TE)SOF+RBV 12 Weeks GT2SOF+RBV 24 Weeks GT3Total
Hispanic or Latino40105
Not Hispanic or Latino95596115
Unknown or Not Reported00000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)LDV/SOF 12 Weeks GT1 or GT4LDV/SOF 24 Weeks GT1 (TE)SOF+RBV 12 Weeks GT2SOF+RBV 24 Weeks GT3Total
Black or African American1811020
White7548592
Asian40116
Other20002
Cirrhosis Status
Cirrhosis Status(participants)LDV/SOF 12 Weeks GT1 or GT4LDV/SOF 24 Weeks GT1 (TE)SOF+RBV 12 Weeks GT2SOF+RBV 24 Weeks GT3Total
No7108483
Yes2852237
HCV Genotype
HCV Genotype(participants)LDV/SOF 12 Weeks GT1 or GT4LDV/SOF 24 Weeks GT1 (TE)SOF+RBV 12 Weeks GT2SOF+RBV 24 Weeks GT3Total
Genotype 198500103
Genotype 20010010
Genotype 300066
Genotype 410001
HCV RNA
HCV RNA(log10 IU/mL)LDV/SOF 12 Weeks GT1 or GT4LDV/SOF 24 Weeks GT1 (TE)SOF+RBV 12 Weeks GT2SOF+RBV 24 Weeks GT3Total
Mean6.2 ± 0.676.0 ± 0.856.2 ± 1.006.6 ± 0.806.2 ± 0.71
HCV RNA Category
HCV RNA Category(participants)LDV/SOF 12 Weeks GT1 or GT4LDV/SOF 24 Weeks GT1 (TE)SOF+RBV 12 Weeks GT2SOF+RBV 24 Weeks GT3Total
< 800,000 IU/mL2322128
≥ 800,000 IU/mL7638592

2 further baseline measures are reported on the registry.

08

Study locations

13 sites
  • Sacramento, California 95817, United States
  • San Diego, California 92103-8651, United States
  • San Francisco, California 94143, United States
  • Washington, District of Columbia 20007, United States
  • Atlanta, Georgia 30308, United States
  • Boston, Massachusetts 02114, United States
  • Boston, Massachusetts 02115, United States
  • Minneapolis, Minnesota 55407, United States
  • Newark, New Jersey 07112, United States
  • New York, New York 10029, United States
  • Rochester, New York 14621, United States
  • Chapel Hill, North Carolina 27599-7584, United States
  • Philadelphia, Pennsylvania 19104, United States
09

References and documents

Publications

  • Walsh C, Workowski K, Terrault N, Sax S, Cohen A, et al. Approved All-Oral Sofosbuvir Regimens Are Safe and Highly Effective in Patients With Hereditary Bleeding Disorders. (2015). Hepatology, 62 (S1): 714A-807A. doi:10.1002/hep.28228
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2014, a primary completion of Aug 2015 and a completion of Aug 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Dec 2016, 1 year 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 18, 2014
First posted
Apr 22, 2014
Start
Apr 2014
Primary completionActual
Aug 2015
CompletionActual
Aug 2015
Results first posted
Dec 6, 2016
Last update
Dec 6, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 6, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02120300
Lead sponsor
Gilead Sciences
Responsible party
Sponsor
First posted
Apr 22, 2014
Start date
Apr 2014
Primary completion
Aug 2015
Completion
Aug 2015
Results posted
Dec 6, 2016
Last update
Dec 6, 2016

Study contacts

Robert H Hyland, DPhil
study director · Gilead Sciences

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Sofosbuvir · Ribavirin

Start the discussion